Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software | News
Search Refinements

IT & Software News

View news from other Pharmaceutical sectors:
91-105 of 1628 results
RXi Pharma gets FDA orphan drug status for melanoma drug samcyprone
By PBR Staff Writer
RXi Pharmaceuticals has secured orphan drug designation from the US Food and Drug Administration (FDA) for its second clinical candidate, Samcyprone, to treat malignant melanoma stage IIb to IV.
Automation > IT & Software > News
CiRA, Takeda to develop iPS cell applications
By PBR Staff Writer
Kyoto University's Center for iPS Cell Research Application (CiRA) and Takeda Pharmaceutical have entered into a ten-year collaboration to jointly develop clinical applications of induced pluripotent stem cells in areas such as heart failure, diabetes mellitus, neurological disorders and cancer immunotherapy.
Automation > IT & Software > News
Horizon gets FDA fast track status for actimmune to treat Friedreich's ataxia
By PBR Staff Writer
Irish biopharmaceutical firm Horizon Pharma has granted fast track designation from the US Food and Drug Administration (FDA) for actimmune (interferon gamma-1b) to treat Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.
Automation > IT & Software > News
Adamas' ADS-5102 gets FDA orphan drug status for LID associated with Parkinson's disease
By PBR Staff Writer
The US Food and Drug Administration (FDA) has granted orphan drug status for Adamas Pharmaceuticals' product candidate ADS-5102 to treat levodopa-induced dyskinesia (LID) associated with Parkinson's disease (PD).
Automation > IT & Software > News
Celgene to buy 15.3 million Mesoblast shares for $45m
By PBR Staff Writer
Australian regenerative medicine firm Mesoblast has entered into an agreement with Celgene, a US-based global biopharmaceutical firm engaged in the development and commercialization of new therapies to treat cancer and immune-inflammatory related diseases.
Automation > IT & Software > News
Acura to develop hydrocodone/APAP tablets using Limitx technology
By PBR Staff Writer
US-based Acura Pharmaceuticals has started developing an immediate-release hydrocodone bitartrate with acetaminophen tablet (hydrocodone/APAP) incorporating its new LIMITX abuse deterrent technology.
Automation > IT & Software > News
Celldex reports positive Phase II EMERGE trial of glembatumumab vedotin to treat breast cancer
By PBR Staff Writer
Celldex Therapeutics has reported positive data from the Phase II EMERGE trial of glembatumumab vedotin, an antibody-drug conjugate, in patients with metastatic breast cancer.
Automation > IT & Software > News
VBI Vaccines, Sanofi Pasteur collaborate to improve vaccine stability
By PBR Staff Writer
US-based biopharmaceutical firm VBI Vaccines has entered into research collaboration with Sanofi Pasteur to use its lipid particle vaccine (LPV) formulation technology to advance the development of a major Sanofi Pasteur vaccine candidate.
Automation > IT & Software > News
Novartis, Aduro Biotech partner to accelerate cancer immunotherapy efforts
By PBR Staff Writer
Swiss pharmaceutical firm Novartis has entered into a major multiyear collaboration with US-based Aduro Biotech in order to accelerate its cancer immunotherapy efforts.
Automation > IT & Software > News
RXi, MirImmune to develop cancer immunotherapies using sd-rxRNA technology
By PBR Staff Writer
US-based RXi Pharmaceuticals and MirImmune have entered into an exclusive license agreement to use RXi's new sd-rxRNA technology in developing new cell-based cancer immunotherapies.
Automation > IT & Software > News
GenVec, TheraBiologics to develop new cancer therapeutics
By PBR Staff Writer
US-based biopharmaceutical firm GenVec has entered into a collaboration agreement with TheraBiologics to develop neural stem cell mediated cancer therapies.
Automation > IT & Software > News
Takeda, Immunogen sign potential $440m drug development deal
By PBR Staff Writer
Japan-based Takeda Pharmaceutical Company and US-based ImmunoGen have signed a drug development agreement that could be worth more than $440m.
Automation > IT & Software > News
GSK, Cold Spring Harbor Lab to develop new drugs for obesity and diabetes
By PBR Staff Writer
US-based Cold Spring Harbor Laboratory has entered into partnership with British pharmaceutical firm GlaxoSmithKline (GSK) to develop new treatments for obesity and type 2 diabetes.
Automation > IT & Software > News
ProMetic completes Phase Ib trial of PBI-4050 in CKD patients
By PBR Staff Writer
Canadian biopharmaceutical firm ProMetic Life Sciences has completed a Phase Ib multi-dose clinical trial of its orally active lead drug candidate, PBI-4050, in patients with chronic kidney disease (CKD).
Automation > IT & Software > News
Cannigistics to offer clinical trials software platform for Canadian medical firm
By PBR Staff Writer
Calyx Bio-Ventures' subsidiary Cannigistics Agri-Solutions (Cannigistics) has entered into a memorandum of understanding (MOU) with an unnamed third party group of Canadian medical specialists with respect to the implementation of a clinical trials software platform.
Automation > IT & Software > News
91-105 of 1628 results